BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.

Narrative review of the literature

“A narrative review of the literature was conducted using PubMed/MEDLINE, Embase, and Cochrane Library from database inception to April 2026.”

BPC-157 (body protection compound 157), a synthetic pentadecapeptide

“BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems.”

Fewer than 30 subjects across three uncontrolled pilot studies

“Available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations.”

Literature search from database inception to April 2026

“A narrative review of the literature was conducted using PubMed/MEDLINE, Embase, and Cochrane Library from database inception to April 2026.”

The primary barrier to clinical translation is the absence of fundamental pharmaceutical science, including characterized formulations and validated pharmacokinetics.

“The primary barrier to clinical translation is not the absence of biological activity, but the absence of fundamental pharmaceutical science: characterized formulations, validated pharmacokinetics, and a coherent drug development strategy.”